ALZN

Alzamend Neuro, Inc. is a preclinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, bipolar disorder, and major depressive disorder. Headquartered in Tampa, Florida, the company operates through its wholly-owned subsidiary, Alzamend Neuro, Inc., and pursues novel therapeutic approaches targeting neurodegenerative and psychiatric conditions. The company's pipeline centers on two lead product candidates: AL001, a patented ionic cocrystal technology designed to treat Alzheimer's disease by inhibiting the formation of amyloid beta plaques and neurofibrillary tangles, and AL002, a method for using a mutant peptide sensitized cell as a therapeutic vaccine to combat Alzheimer's. Additionally, Alzamend has advanced AL003, a patent-pending lithium delivery system intended for treating Alzheimer's, bipolar disorder, and major depressive disorder with improved therapeutic efficacy and reduced toxicity compared to existing lithium treatments. As a development-stage enterprise, the company has not yet generated revenue from product sales and focuses its resources on research and development activities, including preclinical studies and preparing for potential clinical trials. Alzamend operates with a lean structure typical of early-stage biotechnology firms and collaborates with research institutions and contract research organizations to advance its therapeutic candidates through the drug development process.